Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Molecular Partners Ag (MOLN) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Molecular Partners Ag (MOLN) over the last 5 years, with Q3 2025 value amounting to 168.56%.

  • Molecular Partners Ag's EBITDA Margin rose 19737300.0% to 168.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.35%, marking a year-over-year increase of 10621063700.0%. This contributed to the annual value of 0.0% for FY2024, which is 8728600.0% down from last year.
  • Molecular Partners Ag's EBITDA Margin amounted to 168.56% in Q3 2025, which was up 19737300.0% from 1431.03% recorded in Q1 2025.
  • Molecular Partners Ag's EBITDA Margin's 5-year high stood at 88.29% during Q1 2022, with a 5-year trough of 579181884.59% in Q1 2024.
  • Its 5-year average for EBITDA Margin is 59660098.07%, with a median of 565.36% in 2023.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by 2000000000bps in 2023, then skyrocketed by 2000000000bps in 2025.
  • Over the past 5 years, Molecular Partners Ag's EBITDA Margin (Quarter) stood at 599.86% in 2021, then skyrocketed by 110bps to 61.5% in 2022, then crashed by -1307bps to 742.14% in 2023, then surged by 100bps to 0.93% in 2024, then plummeted by -18260bps to 168.56% in 2025.
  • Its last three reported values are 168.56% in Q3 2025, 1431.03% for Q1 2025, and 0.93% during Q4 2024.